DHRHealthcare · Diagnostics & ResearchThe 26 Wall Street analysts covering Danaher Corp. hold a median 12-month price target of $230 — +2.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 23 Sept 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Danaher Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Accruals (42): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DHR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2.8% from it.
Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 July 2026 | Guggenheim | Maintains | Buy | $235 → $200 |
| 22 July 2026 | RBC Capital | Maintains | Outperform | $200 → $215 |
| 22 July 2026 | Stifel | Maintains | Buy | $260 → $220 |
| 22 July 2026 | TD Cowen | Maintains | Buy | $240 → $236 |
| 22 July 2026 | Wells Fargo | Maintains | Equal-Weight | $212 → $195 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $232 → $230 |
| 11 June 2026 | Piper Sandler | Initiates | Neutral | — |
| 3 June 2026 | HSBC | Maintains | Buy | — |
| 2 June 2026 | Wolfe Research | Assumes | Peer Perform | — |
| 27 May 2026 | Citigroup | Downgrade | Neutral | — |
| 15 May 2026 | RBC Capital | Reinstates | Outperform | $200 |
| 23 Apr 2026 | Morgan Stanley | Maintains | Overweight | — |
| 22 Apr 2026 | Baird | Maintains | Outperform | — |
| 22 Apr 2026 | Guggenheim | Maintains | Buy | — |
| 22 Apr 2026 | UBS | Maintains | Buy | — |
| 22 Apr 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 17 Apr 2026 | Baird | Maintains | Outperform | — |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 13 Apr 2026 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DHR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Sept 2026, Danaher Corp. returned +21.3% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 21% of US stocks
Cheaper than 33% of US stocks
Cheaper than 14% of US stocks
Higher than 40% of US stocks
Higher than 77% of US stocks
Higher than 71% of US stocks
Higher than 79% of US stocks
Higher than 79% of US stocks
Higher than 58% of US stocks
Higher than 71% of US stocks
Higher than 15% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Danaher Corp. has a market value of $155.8B and an enterprise value of $179.3B.
Revenue in the twelve months to 30 June 2026: $25.1B. The latest quarter grew 5.5% year on year.
Net income over the same four quarters: $4.0B, a 15.9% net margin.
Diluted earnings per share, trailing twelve months: $5.63.
Free cash flow in the twelve months to 30 June 2026: $5.5B, after $1.1B of capital spending.
Danaher Corp. spent $2.9B on share buybacks and $964.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 39.5×; forward P/E: 23.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.72%, paying out 26% of earnings.
Danaher Corp. employs 58,000 people — $433K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Danaher Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter of 2026 on Wednesday, October 21, 2026, beginning at 8:00 a.m. The announcement was made via a press release on September 22, 2026.
Why it matters — Danaher watchers will know the date and time to tune in for the company's third-quarter earnings results and commentary.
Danaher Corporation announced that its Board of Directors approved a regular quarterly cash dividend of $0.40 per share, payable on October 30, 2026 to shareholders of record on September 30, 2026.
Why it matters — The declaration of a regular quarterly dividend signals continued commitment to returning cash to shareholders on a predictable schedule.
Zacks Investment Research published a piece comparing Elevance Health (ELV) and Danaher (DHR) as potential value stocks in the Medical Services sector, asking which of the two is the better option for investors seeking undervalued stocks.
Why it matters — The article directly evaluates whether Danaher qualifies as an undervalued stock relative to a peer in the medical services space, which could influence how watchers view its valuation.
This item discusses healthcare's shift away from mass-produced, one-size-fits-all treatments toward individualized therapies. These emerging therapies aim to be more effective and carry lower risk of adverse side effects by aligning with a patient's unique biology, with Moderna's cancer vaccine highlighted as an example.
Why it matters — A DHR watcher would care because the broader industry trend toward personalized, biology-aligned treatments could influence demand for the life-sciences tools, diagnostics, and bioprocessing technologies Danaher provides.
Danaher's Biotechnology segment is growing, driven by China demand, bioprocessing activity, and improving discovery markets, which are offsetting regional headwinds. The article examines whether this growth is sustainable.
Why it matters — A DHR watcher would care because the Biotechnology segment is a key growth driver for the company, and the balance of regional headwinds against this momentum affects its overall performance outlook.
The 26 Wall Street analysts covering Danaher Corp. have a median 12-month price target of $230, with estimates ranging from $195 to $310. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 26 analysts covering Danaher Corp., 22 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Danaher Corp. 74 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Sept 2026, Danaher Corp. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
No one can know that. What the data says: the median 12-month target from 26 analysts implies +2.8% from the last close, and Ticker Nerd's factor model ranks Danaher Corp. 74 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Danaher Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $195 to $310 over the next 12 months.
Danaher Corp. returned +21.3% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Danaher Corp. is a global science and technology company focused on biotechnology, life sciences, and diagnostics.
The most recent item we track (PRNewsWire, 22 Sept 2026): "Danaher Schedules Third Quarter 2026 Earnings Conference Call". Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter of 2026 on Wednesday, October 21, 2026, beginning at 8:00 a.m. The announcement was made via a press release on September 22, 2026.
Danaher Corp. is a global science and technology company focused on biotechnology, life sciences, and diagnostics. The company develops and supplies mission-critical tools, consumables, instruments, software, and services used in research, bioprocessing, clinical testing, and laboratory workflows. Its current business is organized around Biotechnology, Life Sciences, and Diagnostics, with offerings that support areas such as biologics manufacturing, molecular and clinical diagnostics, genomics, and analytical instrumentation. Danaher serves customers across healthcare, research, and industrial settings, helping laboratories and life sciences organizations improve efficiency, precision, and productivity. Headquartered in Washington, D.C., Danaher operates through a portfolio of specialized operating companies that provide products and solutions for scientific discovery, disease detection, and the production of biologic therapies.
CEO Mr. Rainer M. Blair · 58,000 employees · United States · https://www.danaher.com
